Moderna, Inc. Common Stock MRNA

The Motley Fool 14 nov

Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.

Zacks Investment Research 13 nov

Moderna outlined its growth strategy at its 2026 Analyst Day, highlighting oncology as a key long-term opportunity with intismeran autogene for melanoma treatment. However, shares fell 7% as the company projected $4 billion in 2027 cash costs and $4-$4.5 billion annually through 2030, while providing limited visibility into 2027 and longer-term revenue growth.

Zacks Investment Research 12 nov

Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.

Zacks Investment Research 11 nov

RSPH, an equal-weight healthcare ETF managed by Invesco, has delivered strong year-to-date returns of 30.11% and 12-month returns of 36.18% as of November 11, 2026. With $1.04 billion in assets and a 0.40% expense ratio, it provides diversified exposure to 64 healthcare holdings. However, investors seeking lower-cost alternatives may consider VHT (0.09% expense ratio) or XLV (0.08% expense ratio), which track traditional market-cap weighted healthcare indexes.

Zacks Investment Research 10 nov

Advanced Micro Devices (AMD) strengthens its semiconductor market position through strong AI infrastructure demand for EPYC server CPUs and Instinct accelerators, with earnings expected to grow 90.9% in the current quarter and 92.8% for the fiscal year. Moderna raises its 2026 revenue outlook following stronger-than-expected Q3 sales, with third-quarter revenues increasing 29% year-over-year, supported by increased COVID vaccine demand and international partnerships.